Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization
- PMID: 12790210
- DOI: 10.1017/s0265021503000589
Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization
Abstract
Background and objective: We investigated the following aspects of pharmacokinetic-guided total intravenous anaesthesia with remifentanil and propofol in patients undergoing surgical myocardial revascularization: anaesthetic efficacy, haemodynamic effects, impact on extubation of the trachea and analgesia after operation.
Methods: Thirty-two patients undergoing on-pump coronary bypass surgery received intravenous anaesthesia with remifentanil and propofol. Both drugs were dosed and titrated based on computer-assisted pharmacokinetic models to maintain constant plasma concentrations. The propofol target plasma concentration was 1.2 microg mL(-1) throughout the procedure. A remifentanil target plasma concentration of 8 ng mL(-1) was achieved over 2 min for induction. After tracheal intubation, the opioid plasma concentration was reduced to 4 ng mL(-1), and then titrated up to 8 ng mL(-1) during surgery. Postoperative analgesia was managed with remifentanil infusion until 4 h after tracheal extubation, and a continuous infusion of tramadol was started 1 h before the remifentanil was stopped.
Results: After induction of anaesthesia, heart rate (-20%) and cardiac index (-6%) decreased significantly. No hypotensive episodes (mean arterial pressure < 60 mmHg) occurred. Intraoperative haemodynamics were stable. Three cases of myocardial ischaemia were detected: two by transoesophageal echocardiography and one with ST-segment monitoring. The duration of postoperative mechanical ventilation of the lungs was 95 +/- 13 min and the time to extubation was 150 +/- 18 min. Postoperative analgesia was satisfactory in all patients.
Conclusions: Pharmacokinetic-based total intravenous anaesthesia with remifentanil and propofol provides adequate anaesthesia during coronary surgery with cardiopulmonary bypass and allows safe early extubation after operation.
Similar articles
-
Continuous infusion of remifentanil and target-controlled infusion of propofol for patients undergoing cardiac surgery: a new approach for scheduled early extubation.J Cardiothorac Vasc Anesth. 2000 Feb;14(1):29-35. doi: 10.1016/s1053-0770(00)90052-1. J Cardiothorac Vasc Anesth. 2000. PMID: 10698389 Clinical Trial.
-
Impact of perioperative lidocaine infusion and bis monitorization on remifentanil dosage in hypotensive anesthesia.Eur Rev Med Pharmacol Sci. 2014;18(4):559-65. Eur Rev Med Pharmacol Sci. 2014. PMID: 24610623
-
Target-controlled remifentanil in combination with propofol for spontaneously breathing day-case patients.Anaesthesia. 1999 Nov;54(11):1028-31. doi: 10.1046/j.1365-2044.1999.00951.x. Anaesthesia. 1999. PMID: 10540089 Clinical Trial.
-
Intravenous anaesthesia: new drugs, new concepts, and clinical applications.Can J Anaesth. 1996 May;43(5 Pt 2):R142-54. doi: 10.1007/BF03011676. Can J Anaesth. 1996. PMID: 8706217 Review. English, French. No abstract available.
-
Alternatives to remifentanil for the analgesic component of total intravenous anaesthesia: a narrative review.Anaesthesia. 2023 May;78(5):620-625. doi: 10.1111/anae.15952. Epub 2022 Dec 23. Anaesthesia. 2023. PMID: 36562193 Review.
Cited by
-
Computerized advice on drug dosage to improve prescribing practice.Cochrane Database Syst Rev. 2013 Nov 12;2013(11):CD002894. doi: 10.1002/14651858.CD002894.pub3. Cochrane Database Syst Rev. 2013. PMID: 24218045 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical